Literature DB >> 31026483

Detection and quantification of 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB) from smoker albumin and its potential as a surrogate biomarker of tobacco-specific nitrosamines exposure and bioactivation.

Yi Wang1, Sreekanth Chanickal Narayanapillai1, Qi Hu1, Naomi Fujioka2, Chengguo Xing3.   

Abstract

4-(Methylnitrosamino)-l-(3-pyridyl)-1-butanone (NNK) and N-nitrosonornicotine (NNN), two tobacco specific nitrosamine carcinogens, can form adducts with DNA and proteins via pyridyloxobutylation upon phase I enzyme-mediated bioactivation. Such DNA modifications have been proposed as the root cause to initiate carcinogenesis. Upon hydrolysis, both DNA and protein modifications would release 4-hydroxy-1-(3-pyridyl)-1-butanone (HPB). The released HPB, being tobacco carcinogen specific, has the potential to serve as a surrogate biomarker for both tobacco exposure and carcinogen bioactivation. Because of its easy access, blood is a great source of such investigations with the potential in epidemiological application. HPB quantification from haemoglobin (Hb), however, has been demonstrated with limited success. To further explore this potentially paradigm-shift opportunity, we reported, for the first time, the detection and quantification of HPB from albumin (Alb) adducts formed by the tobacco-specific nitrosamines in mice and in human smokers. The time-course quantitative analysis of HPB from mouse Alb upon NNK exposure suggests that such an Alb adduct is stable. The amounts of HPB from Alb adducts in smoker plasma averaged 1.82 ± 0.19 pg/mg Alb (0.42 to 3.11 pg/mg Alb), which was 36 times the value in nonsmokers (0.05 ± 0.01 pg/mg Alb). Importantly, HPB level from Alb correlated positively with the level of human tobacco exposure estimated by urinary total nicotine equivalent (TNE) (R2 = 0.6170). For comparison, HPB level from Alb was 16.5 times that of Hb (0.12 ± 0.02 pg/mg Hb) in the plasma and red blood cell (RBC) samples of the same smokers. In addition, there was no significant correlation between HPB levels from Hb and TNE (R2 = 0.0719). These data overall suggest that HPB from Alb adducts can serve as a surrogate biomarker to monitor the level of tobacco exposure and carcinogenic nitrosamine bioactivation.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HPB; NNK; NNN; Protein biomarker; Smoker; Tobacco

Mesh:

Substances:

Year:  2019        PMID: 31026483      PMCID: PMC6551521          DOI: 10.1016/j.toxlet.2019.04.020

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  4 in total

1.  The Impact of One-week Dietary Supplementation with Kava on Biomarkers of Tobacco Use and Nitrosamine-based Carcinogenesis Risk among Active Smokers.

Authors:  Yi Wang; Sreekanth C Narayanapillai; Katelyn M Tessier; Lori G Strayer; Pramod Upadhyaya; Qi Hu; Rick Kingston; Ramzi G Salloum; Junxuan Lu; Stephen S Hecht; Dorothy K Hatsukami; Naomi Fujioka; Chengguo Xing
Journal:  Cancer Prev Res (Phila)       Date:  2020-02-26

2.  Characterization of adductomic totality of NNK, (R)-NNAL and (S)-NNAL in A/J mice, and their correlations with distinct lung carcinogenicity.

Authors:  Qi Hu; Pramod Upadhyaya; Stephen S Hecht; F Zahra Aly; Zhiguang Huo; Chengguo Xing
Journal:  Carcinogenesis       Date:  2022-03-24       Impact factor: 4.944

3.  LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner.

Authors:  Tengfei Bian; Yuzhi Wang; Jordy F Botello; Qi Hu; Yunhan Jiang; Adriana Zingone; Haocheng Ding; Yougen Wu; F Zahra Aly; Ramzi G Salloum; Graham Warren; Zhiguang Huo; Bríd M Ryan; Lingtao Jin; Chengguo Xing
Journal:  Oncogene       Date:  2022-07-14       Impact factor: 8.756

Review 4.  Regulatory function of peroxiredoxin I on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung cancer development.

Authors:  Hu-Nan Sun; Chen-Xi Ren; Yi-Xi Gong; Dan-Ping Xie; Taeho Kwon
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.